Parkinson Gene Therapy Shows Stability, Some Improvements in ON/OFF Time Disease Measures
Based on these data, the phase 2 Regenerate PD trial of AB-1005 will begin enrolling later this year.
NRTX-1001 Cell Therapy Shows Promise for Drug-Resistant Mesial Temporal Lobe Epilepsy
The single-administration allogeneic cell therapy has shown positive safety—and signs of efficacy—in preliminary data from the first 2 patients dosed with the Neurona Therapeutics’ product.
Stem Cell Treatment Shows Benefit in Traumatic Brain Injury
Peter J. McAllister, MD, FAAN, presented promising data from the phase 2 STEMTRA trial at AAN 2022.
Stem Cell Therapy for Spinal Cord Injury on Pace to Soon Enter Human Phase Testing
In an AAN plenary talk, Mark H. Tuszynski, MD, PhD, detailed the work he and colleagues have done to push stem cell therapy from the lab to the clinic to improve care for spinal cord injury.
